Ardelyx, Inc. (ARDX): Operating Cash Flow
-$42.48M
Year ended 2025-12-31
-$17.32M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$42.48M | n/m | 2026-02-19, From 2025-01-01 |
| 2024-12-31 | -$44.81M | n/m | 2026-02-19, From 2024-01-01 |
| 2023-12-31 | -$89.72M | n/m | 2026-02-19, From 2023-01-01 |
| 2022-12-31 | -$70.04M | n/m | 2025-02-20, From 2022-01-01 |
| 2021-12-31 | -$152.55M | n/m | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | -$81.44M | n/m | 2023-03-02, From 2020-01-01 |
| 2019-12-31 | -$76.48M | n/m | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | -$70.27M | n/m | 2021-03-08, From 2018-01-01 |
| 2017-12-31 | -$65.19M | n/m | 2020-03-06, From 2017-01-01 |
| 2016-12-31 | -$92.53M | n/m | 2019-03-06, From 2016-01-01 |
| 2015-12-31 | -$71.84M | n/m | 2018-03-14, From 2015-01-01 |
| 2014-12-31 | $13.40M | +639.8% | 2017-02-17, From 2014-01-01 |
| 2013-12-31 | $1.81M | -91.8% | 2016-03-04, From 2013-01-01 |
| 2012-12-31 | $21.98M | n/a | 2015-03-05, From 2012-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Ardelyx, Inc. (ARDX) | 2025-12-31 | -$42.48M | n/m |
| Innoviva, Inc. (INVA) | 2025-12-31 | $196.93M | +4.4% |
| Sinovac Biotech Ltd (SVA) | 2025-12-31 | -$512.18M | n/m |
| Arcutis Biotherapeutics, Inc. (ARQT) | 2025-12-31 | -$5.62M | n/m |
| Zai Lab Ltd (ZLAB) | 2025-12-31 | -$150.79M | n/m |
| MannKind Corp (MNKD) | 2025-12-31 | $18.25M | -57.1% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $35.32M | +39.6% |
| Travere Therapeutics, Inc. (TVTX) | 2025-12-31 | $37.78M | n/m |
| BridgeBio Pharma, Inc. (BBIO) | 2025-12-31 | -$445.91M | n/m |
Compare ARDX, INVA, SVA, ARQT side by side · Screen every company in Pharmaceutical Preparations ↗